Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Seattle, Washington 98109


Purpose:

A single arm dose optimization study in which all patients are given a fixed dose of Cytoxan (4 x 50 mg/kg) plus ATG (3 x 30 mg/kg) and the TBI dose starting at 3 x 200 cGy is escalated or de-escalated dependent upon engraftment and toxicity.


Criteria:

Inclusion Criteria: - Life-threatening marrow failure of nonmalignant etiology; - failure to respond to the best available immunosuppressive treatment; - lack of a HLA-identical family member Exclusion Criteria: - Severe disease other than aplastic anemia that would severly limit the probability of survival during the graft procedure; - HIV seropositive patients; - clonal abnormalities or myelodysplastic syndrome;


NCT ID:

NCT00144729


Primary Contact:

Principal Investigator
Joachim Deeg, M.D.
Fred Hutchinson Cancer Research Center


Backup Contact:

N/A


Location Contact:

Seattle, Washington 98109
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 11, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.